New Mexico Health Reporter
SEE OTHER BRANDS

Top health and wellness news from New Mexico

New Mexico Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Health Reporter.

Press releases published on June 26, 2025

Ultrack Systems Inc. (OTC: MJLB) Launches “PUR Rx” — A Scalable Digital Healthcare Platform Through Joint Venture with Synergy Health Rx Corp.

Ultrack Systems Inc. (OTC: MJLB) Launches “PUR Rx” — A Scalable Digital Healthcare Platform Through Joint Venture with Synergy Health Rx Corp.

CONCORD, Ontario, June 26, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB) is excited to announce the official launch of PUR Rx, a next-generation digital health platform formed through a 50/50 joint venture with Synergy Health Rx Corp. Designed …

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases

ASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of a new episode …

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

LITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of …

Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer

Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer

Brings 20+ years of revenue growth leadership in laboratory testing, clinical diagnostics and global expansion Led successful organizational turnarounds and growth strategies at both Boston Heart Diagnostics and Genova Diagnostics Extensive track record in …

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, …

Cancer treatments and Panama Canal efficiency: Purdue Innovates Incubator funds projects to advance university innovations

Cancer treatments and Panama Canal efficiency: Purdue Innovates Incubator funds projects to advance university innovations

WEST LAFAYETTE, Ind., June 26, 2025 (GLOBE NEWSWIRE) -- Purdue University researchers in the colleges of Agriculture, Engineering and Science have received $100,000 from the Trask Innovation Fund to develop Purdue-owned intellectual property for commercial …

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Annovis to Attend the AAIC 2025 with Four Poster Presentations

MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and …

Labviva Automates Chemical Supply Chain for the Life Sciences Industry

Labviva Automates Chemical Supply Chain for the Life Sciences Industry

BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- The life sciences chemical supply chain has traditionally been a bottleneck to R…

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer

ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group …

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” …

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

KNOXVILLE, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by Christine Chung, MD and her team (the “Chung Lab”) at Moffitt …

Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD) Recommendation reflects ZORYVE’s proven efficacy, safety, and …

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

SOLANA BEACH, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, …

Confluent Health Launches Groundbreaking Scholars Program Designed to Eliminate Student Debt for Future Physical Therapists

Confluent Health Launches Groundbreaking Scholars Program Designed to Eliminate Student Debt for Future Physical Therapists

LOUISVILLE, Ky., June 26, 2025 (GLOBE NEWSWIRE) -- Confluent Health, a leading innovator in musculoskeletal (MSK) care, has launched the Confluent Health Scholars Program, an industry-leading initiative designed to eliminate the biggest barrier to entry …

Montauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider Foundation

Montauk Brewing Celebrates 13 Years of Brewing with Faherty Collaboration and Beach Clean Up with the Surfrider Foundation

MONTAUK, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Montauk Brewing Co., the brewery known for capturing the essence of coastal living and a craft beer brand by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), is partnering with premium lifestyle …

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …

GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 …

Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting

Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting

JERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613 on trabecular and cortical bone was …

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service